Hemophilia A – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of hemophilia A for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s hemophilia A forecast will answer the following questions:

  • How will improvements in survival change the number of people living with a diagnosis of hemophilia A?
  • Of all people diagnosed with hemophilia A, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hemophilia A over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 31 hemophilia A patient populations, including the following:

  • Non-drug-treated prevalent cases of mild hemophilia A.
  • Prevalent cases of moderate inhibitor-negative hemophilia A.
  • Prevalent cases of low-inhibitor-titer hemophilia A.
  • Diagnosed prevalent cases of hemophilia A.
  • Prevalent cases of mild hemophilia A.
  • Prevalent cases of moderate hemophilia A.
  • Drug-treated prevalent cases of moderate hemophilia A.
  • Prevalent cases of inhibitor-positive moderate hemophilia A.
  • Total prevalent cases of inhibitor-positive hemophilia A.

Note: Coverage may vary by country.

launch Related Market Assessment Reports